🇺🇸 O6-benzylguanine in United States

79 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Headache — 11 reports (13.92%)
  2. Mental Status Changes — 10 reports (12.66%)
  3. Pyrexia — 10 reports (12.66%)
  4. Staphylococcal Infection — 10 reports (12.66%)
  5. Pulmonary Embolism — 9 reports (11.39%)
  6. Convulsion — 6 reports (7.59%)
  7. Deep Vein Thrombosis — 6 reports (7.59%)
  8. Post Procedural Complication — 6 reports (7.59%)
  9. Somnolence — 6 reports (7.59%)
  10. Extradural Haematoma — 5 reports (6.33%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is O6-benzylguanine approved in United States?

O6-benzylguanine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for O6-benzylguanine in United States?

Case Comprehensive Cancer Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.